Nuwellis报告说,在Aquadex疗法的驱动下,2024年Q3的收入增加了28%。 Nuwellis reports a 28% revenue increase in Q3 2024, driven by its Aquadex therapy focus.

医疗器械公司 Nuwellis 报告了 2024 年第三季度的初步业绩,显示儿科部门的收入增长了 28%,毛利率为 70%,运营成本比 2023 年降低了 30%. Nuwellis, a medical device company, reported preliminary results for Q3 2024, highlighting a 28% revenue increase in the Pediatric sector, a 70% gross margin, and a 30% reduction in operating costs compared to 2023. 该公司的重点是Aquadex超渗透疗法,其效果已经提高。 The company is focused on the Aquadex ultrafiltration therapy, which has shown increased efficacy. Nuwellis将在2024年11月11日公布所有结果, Nuwellis will release full results and hold an earnings call on November 11, 2024.